Advancing with cancer immunotherapeutics: CD29+ regulatory T cell antagonism

Advancing with cancer immunotherapeutics: CD29⁺ regulatory T cell antagonism

Gut. 2024 Feb 23;73(3):391-392. doi: 10.1136/gutjnl-2023-331048.

Francisco Javier Cubero^{1

2}, Pablo Sarobe^{3

4

5}, Gisa Tiegs⁶

¹ Immunology, Ophthalmology and ENT, Complutense University of Madrid Faculty of Medicine, Madrid, Spain.
² Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain.
³ Centre for Biomedical Research, Network on Liver and Digestive Diseases(CIBEREHD), Madrid, Spain.
⁴ Programa de Inmunología e Inmunoterapia, Centro de Investigación MédicaAplicada (CIMA, CCUN), Universidad de Navarra, Pamplona, Spain.
⁵ IdiSNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
⁶ Insitute of Experimental Immunology and Hepatology, University Medical Center, Hamburg, Germany g.tiegs@uke.de.

No abstract available

Keywords: HEPATOCELLULAR CARCINOMA; IMMUNOTHERAPY; INTEGRINS; LIVER; T LYMPHOCYTES.